ABSTRACT
Objective: To summarize the typical experiences and practices based on the quality evaluation of medical consumables in foreign countries and the practice of drug bidding in China,and to explore the establishment of a bidding grouping scheme for medical consumables in China. Methods: Using literature analysis and evaluation method of combing foreign countries typical measures of medical consumables quality assessment,this paper summa-rized the construction of index system of bidding in China Pharmaceutical Group, and used simple statistical data to reflect the present policy of China's medical supplies such as lack of relevant policies,different levels of quality etc.. Results:There are many problems in the quality evaluation of medical consumables in China. However, the typical measures of extraterritorial quality evaluation and the practice of pharmaceutical bidding in China provide a solid theo-retical and practical basis for the establishment of medical consumable supplies bidding grouping. Conclusion:Estab-lishing bidding grouping scheme is necessary in the Chinese Medical supplies context. Based on a clear difference be-tween medical supplies and medicines,and according to the"three stage"our conceptualization gradually improved. On the basis of the existing data and practical situation,the establishment of scientific selection index bidding group division standard,has been in the exploration of the formation of China's medical supplies bidding grouping scheme.
ABSTRACT
OBJECTIVE: To analyze the safety monitoring effects of pediatric drug data protection regime in the US and provide the suggestions to improve the safety of pediatric drugs in China. METHODS: Theoretical analysis and case study of Duragesic (Fentanyl transdermal patch). RESULTS: The pediatric drug data protection regime promoted safety monitoring effectively. CONCLUSION: II is necessary to establish pediatric drug data protection system in China by referring to the experience of US, to enhance the lilecycle risk management and the responsibilities of enterprises, so as to improve the safety of pediatric drug.
ABSTRACT
OBJECTIVE: To provide domestic innovative pharmaceutical enterprises practical advice on patent strategy and innovation capacity-building. METHODS: Choose the first class innovative drug NBP as study subject, make an empirical study from three aspects, including patent creation, management and implementation, about how to take full advantage of the national innovation policies and patent strategy to improve the innovation capability of enterprises to ensure its sustainable development. RESULTS: The patent strategy of NBP turns out to be a very big success. CONCLUSION: CSPC has developed a virtuous cycle, in which patent strategy and innovation capacity-building facilitate each other, its successful experience is worth learning for high-tech enterprises.